RayzeBio, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RYZB research report →
About the company
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
- CEO
- Kenneth Song
- IPO
- 2023
- Employees
- 88
- HQ
- DE, US
Price Chart
- Market Cap
- $3.75B
- P/E
- -35.71
- P/S
- 0.00
- P/B
- -22.02
- EV/EBITDA
- -54.15
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 82.72%
- ROIC
- -22.86%
- Revenue
- $0 · 0.00%
- Net Income
- $-68,600,000 · -132.98%
- EPS
- $-1.75 · -139.73%
- Op Income
- $-72,120,000
- FCF YoY
- -65.51%
- 52W High
- $62.51
- 52W Low
- $17.95
- 50D MA
- $55.78
- 200D MA
- $36.72
- Beta
- 3.79
- Avg Volume
- 745.49K
Get TickerSpark's AI analysis on RYZB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 26, 24 | VIKING GLOBAL INVESTORS LP | other | 1,743,556 |
| Sep 19, 23 | Redmile Group, LLC | other | 498,510 |
| Sep 19, 23 | Redmile Group, LLC | other | 494,687 |
| Sep 19, 23 | Redmile Group, LLC | other | 864,509 |
| Sep 19, 23 | Redmile Group, LLC | other | 432,254 |
| Sep 19, 23 | Redmile Group, LLC | other | 498,510 |
| Sep 19, 23 | Redmile Group, LLC | other | 864,509 |
| Sep 19, 23 | venBio Global Strategic Fund III, L.P. | other | 247,343 |
| Sep 19, 23 | venBio Global Strategic Fund III, L.P. | other | 1,123,862 |
| Sep 19, 23 | venBio Global Strategic Fund III, L.P. | other | 3,786,957 |
Our RYZB coverage
Recent articles, reports, and earnings notes.
No research on RYZB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RYZB report →Similar companies
Peers in the same neighborhood.